Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> MutationBella Kaufman, Susan M. Domchek, Ronnie Shapira‐Frommer et al.|Journal of Clinical Oncology|2014Cited by 1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, James Carmichael, Mark E. Robson et al.|The Lancet|2010Cited by 1.6k
Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Frances R. Balkwill, Jermaine Coward et al.|Nature reviews. Cancer|2011Cited by 1.5k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupKathryn Alsop, Gillian Mitchell, Sián Fereday et al.|Journal of Clinical Oncology|2012Cited by 1.2k
Cancer of the ovary, fallopian tube, and peritoneum: 2021 updateJonathan S. Berek, Michael Friedländer, Malte Renz et al.|International Journal of Gynecology & Obstetrics|2021Cited by 499